What's breaking now, across thousands of outlets.
MUNICH — Arrowhead is on course to crash Ionis Pharmaceuticals’ party. Arrowhead’s RNA interference drug Redemplo looked safer as well as effective in two late-stage trials in patients with high levels of dangerous fatty molecules called ...
We haven't written up this one. Endpoints News has the full story — the link below goes straight to it.
com. More men are seeking ways to maintain a youthful and attractive appearance as they age. The trend is not simply about looking younger, but rather about reflecting the vitality and confidence they…
(MedPage Today) -- When I started my career as a pulmonologist, my time was spent caring for patients -- listening to their concerns, researching care, talking through treatment options, and…
The discussion about diarrhea has increased lately, especially with the rise of cyclosporiasis. Although unpleasant, it is manageable and can be treated at home In the US, people are discussing…
The first-ever European Society of Cardiology Guidelines on the management of cardiovascular disease and chronic kidney disease have been developed in collaboration with the European Renal…
